AI Found The Key To Ending Baldness (And It’s Not What You Think)

Scientific Concepts, Discoveries, and Biological Phenomena

Androgenetic alopecia (male/female pattern baldness)

• Described as hair loss driven by the hormone DHT (dihydrotestosterone).

Limitations of current DHT-focused therapies

• Finasteride/dutasteride (pills) and topical lotions aim to block DHT, but many people slow hair loss rather than regrow substantial hair.
• Minoxidil is mentioned as a common regrowth treatment.

AI-driven drug discovery approach

• A company used artificial intelligence on a supercomputer to search for a new hair-loss therapy.
• The AI designed a custom antibody-like therapy, framed as a precision “security key” targeting a specific body “lock.”

New biological target: the prolactin receptor

• The designed antibody targets the prolactin receptor.
• Prolactin is typically associated with breastfeeding, making this repurposing surprising in the presentation.

Rationale for safety via genetics

• People who naturally lack an active prolactin receptor (due to genetics) were reported to have:
  • No fertility problems
  • No major developmental changes
  • No serious hormonal issues
• This is used to argue that blocking the prolactin receptor may be safer than other hormonal interventions.

Preclinical efficacy in animals (hairless mice)

• In hairless mice, the antibody reportedly regrew all hair in ~22 days.
• Compared with minoxidil, which reportedly achieved about one-third of that regrowth in the same timeframe.
• A caveat is emphasized: mouse results may not translate directly to humans.

Clinical Trial Methodology / Study Design (as described)

• Study phase: Phase 1
• Drug: ABS 2011 (anti–prolactin receptor antibody)
• Indications mentioned: androgenetic alopecia and endometriosis
• Design: Randomized, double-blind, placebo-controlled
• Participants: 32 healthy adults
• Groups / dosing: four IV dose groups plus placebo:
  • 150 mg
  • 450 mg
  • 900 mg
  • 1,800 mg
  • plus a placebo group
• Data collection cutoff: up to June 8
• Reported safety outcomes:
  • No serious side effects
  • Most serious: moderate headache in the 900 mg group (researchers considered it unlikely related)
  • Most common: mild headache in 4 participants
• Pharmacokinetics: estimated half-life ≥ 65 days
• Immunogenicity: no antibodies detected against the medication
• Next stage: Phase 2A
  • Uses subcutaneous injection
  • Includes participants who actually have androgenetic alopecia
  • Goal: assess hair regrowth efficacy in humans

Reported Development Timeline / Expectations

• Preliminary efficacy for Phase 2A: second half of the year (“this year” in the subtitles)
• Full data: early 2027
• Additional claims: by end of 2026, ABS 2011 results expected in people with androgenetic alopecia after 13 and 26 weeks

Other Treatments Mentioned (context only)

Several other hair-loss drug candidates are named as under investigation:

• GT20029
• PP 405
• “Brazula” (spelled as shown in subtitles)
• “prolutite” (spelled as shown in subtitles)

(They are mentioned without additional methodology details.)

Researchers / Sources Featured (as named in the subtitles)

• Takasi Suji

  • Japanese scientist mentioned as important for “hair cloning” (described outside the main ABS 2011 trial section).

• Absy Corporation / APS

  • Credited as the company source for ABS 2011 and the clinical trial (mentioned multiple times).